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Abstract
Background: The MUC1 gene encodes a mucin glycoprotein(s) which is basally expressed in most
epithelial cells. In breast adenocarcinoma and a variety of epithelial tumors its transcription is dramatically
upregulated. Of particular relevance to breast cancer, steroid hormones also stimulate the expression of
the MUC1 gene. The MUC1 gene directs expression of several protein isoforms, which participate in many
crucial cell processes. Although the MUC1 gene plays a critical role in cell physiology and pathology, little
is known about its promoter organization and transcriptional regulation. The goal of this study was to
provide insight into the structure and transcriptional activity of the MUC1 promoter.
Results: Using TRANSFAC and TSSG soft-ware programs the transcription factor binding sites of the
MUC1 promoter were analyzed and a map of transcription cis-elements was constructed. The effect of
different MUC1 promoter regions on MUC1 gene expression was monitored. Different regions of the
MUC1 promoter were analyzed for their ability to control expression of specific MUC1 isoforms.
Differences in the expression of human MUC1 gene transfected into mouse cells (heterologous artificial
system) compared to human cells (homologous natural system) were observed. The role of estrogen on
MUC1 isoform expression in human breast cancer cells, MCF-7 and T47D, was also analyzed. It was shown
for the first time that synthesis of MUC1/SEC is dependent on estrogen whereas expression of MUC1/TM
did not demonstrate such dependence. Moreover, the estrogen receptor alpha, ERα, could bind in vitro
estrogen responsive cis-elements, EREs, that are present in the MUC1 promoter. The potential roles of
different regions of the MUC1 promoter and ER in regulation of MUC1 gene expression are discussed.
Conclusion: Analysis of the structure and transcriptional activity of the MUC1 promoter performed in
this study helps to better understand the mechanisms controlling transcription of the MUC1 gene. The
role of different regions of the MUC1 promoter in expression of the MUC1 isoforms and possible function
of ERα in this process has been established. The data obtained in this study may help in development of
molecular modalities for controlled regulation of the MUC1 gene thus contributing to progress in breast
cancer gene therapy.
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Background
The MUC1 gene belongs to a family of genes encoding
mucin glycoproteins [1]. MUC1 is normally expressed on
the apical surface of mammary epithelial cells. However,
in breast adenocarcinoma and a number of epithelial
tumors, MUC1 is upregulated with aberrant expression
over the entire cell surface [1-4]. This characteristic makes
the MUC1 protein valuable as a marker in breast cancer
diagnostics and prognosis [2]. In addition to epithelial
cells, expression of MUC1 glycoprotein has been observed
also in hematopoetic cells, T- and B-lymphocytes, hepato-
cytes, myocytes and nerve cells [5,6].
Molecular studies have revealed several MUC1 protein
isoforms: MUC1/TM, MUC1/SEC, MUC1/Y, MUC1/X
and MUC1/Z [4,7,8]. The MUC1 isoforms demonstrate a
diversity of properties and functions which may explain
the crucial role of the MUC1 protein in many physiologi-
cal and pathological processes. It participates in signal
transduction, blastocyst implantation, epithelial cell mor-
phogenesis, cellular adhesion, T-cell immunosuppression
and matastases progression [9]. Expression of the MUC1/
TM, MUC1/X, MUC1/Y and MUC1/Z is associated with
the presence of malignancy, whereas expression of
MUC1/SEC is observed mostly in non-malignant tissue
[10].
The coordinated expression of multiple MUC1 isoforms
in a wide spectrum of cells suggests a fine-tuning of mech-
anisms regulating MUC1 transcription in a cell- and tis-
sue-specific manner. One of the essential steps of
transcriptional regulation is binding of transcription fac-
tors to transcription cis-elements in promoter DNA. The
combinatorial arrangement of cis-elements in a gene pro-
moter is one of the important factors that determine gene
transcription. For this reason, identification of cis-ele-
ments and their arrangement in a given promoter is of
great importance and may provide clues to unravel poten-
tial mechanisms regulating transcription of a given gene.
The computer analysis of promoter DNA sequences is an
appropriate method for identification of transcription cis-
elements. Previously, we analyzed the content and com-
position of transcription cis-elements in the 3'-end 725 bp
fragment of the MUC1 promoter [11]. In this relatively
short fragment we found more than one hundred cis-ele-
ments demonstrating the high level of MUC1 promoter
complexity both structurally and functionally. Nonethe-
less, these findings represented only a small portion of the
cis-elements operating in the full length MUC1 promoter.
One of the goals of this study was to further analyze the
content and arrangement of transcription factor binding
sites in the full 2872 bp MUC1 promoter and to construct
a MUC1 cis-element map.
Many studies of transcriptional regulation have been per-
formed by transient transfection. Usually, in such experi-
ments, a recombinant plasmid containing a promoter (or
part of it) obtained from a gene of a given type (human,
for example) and coding region (test-gene) from a gene of
another type (bacterial CAT-gene, luciferase gene) is used.
This artificial construct is transfected into cells (mouse, for
example) that naturally do not express the gene of inter-
est. Analysis of endogenous genes in homologous systems
is more biologically relevant than these artificial set-ups
for several reasons. It is known that introns play impor-
tant role in transcriptional regulation [12], however, in
artificial systems they are excluded from this process. The
results of transcription, as evaluated by RT-PCR, depend
on the stability of nuclear RNA-transcripts that, in turn, is
determined by the gene's 3'UTR [13]. It should be under-
scored that usage of transfection assays with a promoter
separated from its exon-intron sequences and 3'UTR, may
distort the natural mechanisms of transcriptional regula-
tion of the given gene. The inadequacy of the described
system for analysis of natural regulation of transcription
becomes even more obvious when properties of transcrip-
tion factors of different origins are taken into account. For
instance, in certain conditions the affinity and binding
specificity of mouse transcription factors for ligands and
cis-elements may be different from those of corresponding
human transcription factors or transcription factors of
other non-relative species [14,15]. This may lead to aber-
rant transcription of a human gene in mouse cells upon
transient transfection. Therefore, for obtaining more
objective information on the promoter activity and tran-
scriptional regulation, it is important to study the expres-
sion of a gene both in transiently transfected heterologous
cells and in cells in which the gene of interest is expressed
endogenously. In this study, we investigated the roles of
different regions of the MUC1 promoter in expression of
human MUC1 isoforms using transient transfection.
However, in addition to ectopic transfection assays we
also investigated expression of the human MUC1 gene in
human epithelial cells.
MUC1 expression is predominantly hormonally regulated
[16-20]. Although intensively studied [16-18], the mech-
anisms of steroid regulation of MUC1 transcription are
still obscure. Estrogen increases MUC1 expression [17],
whereas the antiestrogen ICI 164,387 inhibits estradiol-
stimulated MUC1 synthesis [19]. These results imply a
specific effect of estrogen and suggest that nuclear estro-
gen receptor(s) are likely to be involved in MUC1 tran-
scription [19]. However, in the mouse MUC1 promoter
the estrogen receptor (ER) does not bind directly to estro-
gen receptor cis-element, ERE [18]. Among the cis-ele-
ments found in the 725 bp fragment of the human MUC1
promoter, we have detected several sites homologous to
ERE [11]. In this study of the full MUC1 promoter, weMolecular Cancer 2006, 5:57 http://www.molecular-cancer.com/content/5/1/57
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identified an additional ERE. We analyzed the role of
estrogen in regulation of the MUC1 transcription in
human epithelial cells in vivo and have investigated the
potential of ER to bind cis-ERE of the human MUC1 pro-
moter in vitro. We showed for the first time that estrogen
differentially regulates expression of the MUC1 isoform
specific mRNAs in human breast cancer cells: it activates
expression of the MUC1/SEC isoform but does not affect
expression of the MUC1/TM mRNA. By electrophoresis
mobility shift assay (EMSA) we were able to demonstrate
that ERα present in T47D cell lysate could directly bind to
MUC1 promoter EREs, thus supporting the hypothesis
that regulation of the MUC1 expression by estrogen may
be realized by ER binding to EREs present in the MUC1
promoter.
Results
Structural analysis of the MUC1 promoter
Using computer analysis of the 2872 bp MUC1 promoter
sequence, we identified multiple transcription factor spe-
cific cis-elements (674 sites in the sense strand and 452
site in the opposite strand) and constructed a map that
shows the arrangement of these elements in the MUC1
promoter ("Additional files 1, 2, 3"). The level of homol-
ogy between the MUC1 cis-elements in our study and cor-
responding consensus sequences was 0.75–1.0. This
facilitated isolation of discrete cis-elements that were
highly homologous to consensus sequences, but demon-
strated a definite degree of freedom in flanking regions.
The analysis of these cis-elements revealed several impor-
tant characteristics of the MUC1 promoter:
1) The numerous cis-elements found in the MUC1 pro-
moter potentially afford gene expression in a wide spec-
trum of cells. Among these elements were ubiquitous
eukaryotic cis-elements as well as mammary, muscle,
liver, hematopoietic and immune cell specific elements.
Additionally, the MUC1 promoter contained cis-elements
found in viral promoters. Some of the elements (Ikarus-2,
AML-1 or YY1) were represented in the promoter by mul-
tiple copies, while the others (NF1-tkII or Evi F) were
unique and appeared in the MUC1 promoter only once
("Additional files 1, 2, 3").
2) Although most eukaryotic promoters usually carry a
single RNA-pol II initiation box (either TATA-box, GC-box
or Initiator) [21-23], the MUC1 promoter carried all three
motifs. Moreover, the MUC1 promoter contained numer-
ous CAP-sites that could function as putative transcription
start sites (TSS). Some of the functionally active TSS have
been experimentally verified [11].
3) One important feature of the MUC1 promoter was an
extensive overlapping and clustering of cis-elements.
Overlapping of cis-elements could facilitate competition
between different transcription factors (see "Additional
files 1, 2, 3"). Competing factors may be agonistic or
antagonistic, either activating or repressing transcription.
For example, at position -2785/-2775 the binding site for
YY1 repressor overlaps the binding site specific for tran-
scriptional activator Pu, while in another cluster (-1432/-
1407), this repressor may compete both with a repressor
(Gfi-1 immunospecific repressor) and with three activa-
tors (immunospecific activator Ikarus, hepatospecific acti-
vator SREBP1 and general activator protein AP1). Thus,
different arrangements of cis-elements in the MUC1 pro-
moter provide conditions for competition of multiple
cell- and tissue-specific transcription factors which, in
turn, might determine cell and tissue specificity of MUC1
gene transcription. The construction of the cis-element
map was the first step in the programmed study of the
MUC1 transcriptional regulation. The map has been
employed to design functional analysis experiments of
transcription factors and their potential to compete for
corresponding cis-elements.
Analysis of MUC1 promoter activity by transient 
transfection assays
In our previous investigations [11] we employed CAT
assays to evaluate the activity of a truncated human MUC1
promoter. In this study, we examined the role of different
domains within the full-length MUC1 promoter in
expression of MUC1 gene. The plasmid, Dpr, based on the
ppolyII backbone was constructed to contain the full
length (-2872/+1) human MUC1 promoter and genomic
sequence of the human MUC1 gene including exons and
introns. Using this plasmid we generated three sequential
deletions from the 5'-end of the MUC1 promoter:
pDprΔ2154 which lacks 2154 base pairs of promoter;
pDprΔ2446 and pDprΔ2839 carrying only 426 and 33
residual nucleotides of the promoter sequence, respec-
tively. These plasmids were used in transient transfection
assays (Fig. 1A).
In mouse breast carcinoma DA3 cells transiently trans-
fected with plasmid Dpr, MUC1/SEC was the only human
MUC1 isoform observed (Fig 1B, lane – 1). When
DprΔ2154 plasmid was expressed in mouse cells, the
MUC1/TM could be detected in addition to MUC1/SEC
mRNA (Fig. 1B, lanes – 4 and 5). However, the level of
MUC1/TM mRNA expression was less than the expression
of MUC1/SEC mRNA. Interestingly, when the plasmid
DprΔ2446 that lacks an additional 292 nucleotides of the
MUC1 promoter was expressed into DA3 cells, the mRNA
levels of MUC1/TM dramatically increased (Fig. 1B, lane
– 8) whereas the expression of MUC1/SEC isoform mRNA
was much less pronounced (Fig. 1B, lane – 7). In cells
over-expressing plasmid DprΔ2839, only MUC1/SEC
mRNA could be detected (Fig. 1B, lane – 10). These results
suggest that expression of MUC1/SEC and MUC1/TM iso-Molecular Cancer 2006, 5:57 http://www.molecular-cancer.com/content/5/1/57
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form specific mRNAs in our experimental system might be
controlled by different regions of the MUC1 promoter.
No expression of MUC1/Y mRNA was observed in any of
our transfection assays (Fig. 1B, lanes – 3, 6, 9 and 12).
The reason for this is presently being studied by using dif-
ferent transfection and PCR parameters and changing gel
running and exposure conditions.
Expression of MUC1 isoform mRNAs in human breast 
cancer cell lines and the role of estrogen in transcriptional 
regulation of the MUC1 gene in vivo
The next step in our investigation was study of the MUC1
transcription in natural conditions. For this purpose we
evaluated expression of the MUC1 isoform specific mRNA
in human breast epithelial cells T47D, MCF7 and MDA-
MB-231. We also used these cells for studying the role of
estrogen and estrogen receptors (ER) in MUC1 transcrip-
tion. In non-treated, ER-negative T47D (T47D, clone 8)
and MDA-MB-231 cells, only MUC1/TM mRNA could be
detected (Fig 2, lanes – 14 and 17, respectively). As
expected, treatment of these cells with estrogen did not
change the pattern of the MUC1 gene expression (data not
shown). When ER-positive T47D cells (T47D, clone 10)
were grown without estrogen also they expressed only
MUC1/TM mRNA (Fig. 2, lane – 8). However, treatment
of these cells with estrogen activated transcription of the
MUC1/SEC mRNA and MUC1/Y mRNAs although the
later one was expressed much less (Fig. 2, lanes – 10 and
Expression of the MUC1 isoform specific mRNA in mouse DA3 cells transfected with plasmids pDpr, pDprΔ2154, pDprΔ2446,  pDprΔ2839 and ppolyIII Figure 1
Expression of the MUC1 isoform specific mRNA in mouse DA3 cells transfected with plasmids pDpr, 
pDprΔ2154, pDprΔ2446, pDprΔ2839 and ppolyIII. DA3 cells were transfected with plasmid DNA. Cells transfected with 
ppolyIII were used as negative controls. DA3 cells stably transfected with MUC1/SEC, MUC1/TM and MUC1/Y cDNA were 
used as positive control. Total RNA was extracted 48 hrs after transfection and cDNA was synthesized. PCR amplification of 
MUC1 isoform specific fragments were performed using isoform specific primers. PCR products were separated by electro-
phoresis on 1.2% agarose gel and stained with ethidium bromide. A – Schematic structure of the pDpr, pDprΔ2154, 
pDprΔ2446, pDprΔ2839 plasmids and the table of the MUC1/SEC, MUC1/TM and MUC1/Y mRNA expression in transfected 
DA3 cells. B – RT-PCR of the MUC1 isoform specific RNA extracted from DA3 cells transiently transfected with indicated 
plasmids. Lane M-DNA marker; lanes 1, 4, 7, 10 and 13 (negative control) – PCR performed with MUC1/SEC specific primers; 
lanes 2, 5, 8, 11 and 14 (negative control) – PCR performed with MUC1/TM specific primers; lanes 3, 6, 9, 12 and 15 (negative 
control) – PCR performed with MUC1/Y specific primers. Positive control: DA3 cells stably transfected with MUC1 isoform 
specific cDNA. Lane SEC – cells expressed MUC1/SEC; lane TM – cells expressed MUC1/TM and lane Y – cells expressed 
MUC1/Y RNAs.
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12, respectivelly). These results imply that estrogen has a
differential effect on the expression of MUC1 isoforms.
Whereas the expression of MUC1/TM does not depend on
estrogen, MUC1/SEC and probably MUC1/Y isoforms are
expressed in an estrogen-dependent manner. In untreated
MCF7 cells, both the MUC1/SEC and MUC1/TM mRNA
are clearly expressed (Fig. 2, lanes – 1 and 2) but MUC1/
Y mRNA was hardly detected (Fig.2, lane – 3). When MCF-
7 cells were treated with estrogen, the expression of
MUC1/SEC and MUC1/Y mRNAs increased (Fig. 2, lanes
4–6).
To clarify the role of estrogen and estrogen receptors (ER)
in transcriptional regulation of the human MUC1 gene,
experiments with antiestrogen 4-hydroxytamoxifen (4-
OHT) were performed. 4-OHT competes with estrogen for
binding to ER thus disrupting the signal transduction orig-
inating from estrogen. Fig. 3 shows that estrogen
increased and 4-OHT somewhat inhibited the expression
of MUC1/SEC mRNA in a dose dependent manner in
both T47D and MCF7 cells (Fig. 3, lanes 2–4 and 5–7,
respectively). MUC1/TM mRNA expression did not
respond to these agents. Expression of MUC1/Y mRNA
was not sensitive to low concentration (0.1 nM and 1 nM
of estrogen (Fig. 3, lanes 2 and 3) but was increased by
high concentration (10 nM) of hormone in both cell lines
(Fig. 3, lane 4). In contrast to MUC1/SEC, expression of
MUC1/Y was not inhibited by 4-OHT (Fig. 3, lanes 5 – 7).
Our results document the differential effect of estrogen
and 4-OHT on the expression of the MUC1 isoform
mRNAs. Since the above experiments suggest an involve-
ment of ER in MUC1 transcriptional regulation at least of
some of its isoforms, next we wished to analyze the bind-
ing of human ERs to the MUC1 promoter cis-estrogen
response element (cis-ERE).
Binding of ERα to cis-ERE in the MUC1 promoter
To investigate the potential binding of ER to the MUC1
cis-ERE we employed electrophoresis mobility shift assays
(EMSAs). It has previously been shown by Western blot
analysis that ERα is the main type of estrogen receptor
expressed in T47D cells [24]. We confirmed this observa-
tion by RT-PCR (data not shown). Taking this into
account, we concentrated our efforts on studying the abil-
ity of the MUC1 EREs to bind ERα.
Nuclear lysate of estrogen-treated T47D cells (clone 10,
ER+) served as a source of ERα. The oligonucleotides uti-
lized in this study were homologous to the six cis-EREs
found in the MUC1 promoter by our bioinformatics
search. The oligonucleotide Vit-ERE originating from the
vitellogenin gene and consisting of a canonical palin-
drome ERE (GGTCANNNTGACC) [25] was used as a pos-
itive control. It contains one direct and one inverted
repeats of consensus sequence (GGTCA) separated by
three intermediate nucleotides. In the MUC1 promoter,
although we did not locate a classical palindrome ERE, a
reminiscent  cis-element sequence (GGACCNCGACC)
structurally similar to Vit-ERE was identified. This cis-ele-
ment, called "putative" ERE-6, was located at the position
-349/-339. Five other half (1/2 of the core sequence)
direct (GGTCA) or inverted (TGACC) sequences were
found at positions -2748/-2744 (ERE-1), -1174/-1170
(ERE-2), -745/-741 (ERE-3), -384/-380 (ERE-4) and -364/
-360 (ERE-5) (see "Additional files 1, 2, 3").
When Vit-ERE was incubated with T47D nuclear lysate,
three main complexes, C1, C2 and C3, were detected (Fig.
4A, lanes 19, 21 and 25). The complex C1 had the highest
gel mobility and apparently represented the simplest
nucleoprotein complex composed of ERα and Vit-ERE oli-
gonucleotide. The complexes C2 and C3, in addition to
Expression of the MUC1 isoform specific mRNA in human mammary epithelial cells detected by RT-PCR Figure 2
Expression of the MUC1 isoform specific mRNA in human mammary epithelial cells detected by RT-PCR. 
Total RNA from human MCF-7, T47D and MDA-231 cells and RNA from mouse DA3 cells stably transfected with MUC1/SEC 
(lane – SEC), MUC1/TM (lane – TM) and MUC1/Y (lane – Y) cDNA (positive controls) were extracted and RT-PCR amplifica-
tion of the MUC1 isoform specific fragments were performed. Lanes 1, 4, 7, 10, 13, 16 and SEC – PCR performed with MUC1/
SEC specific primers; lanes 2, 5, 8, 11, 14, 17 and TM – PCR performed with MUC1/TM specific primers; lane 3, 6, 9, 12, 15, 18 
and Y – PCR performed with MUC1/Y specific primers.
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components present in the complex C1, might contain
also ER-specific cofactors [26].
In our assays, all MUC1 promoter EREs could bind ERα
(Fig. 4A, lanes – 1, 3, 5, 7, 10 and 12). However, the com-
plexes developed with different ERE had different gel
mobilities. The most prominent binding was observed
with "putative" ERE-6 and ERE-2 (Fig. 4A, lanes – 10 and
12, respectively), while the affinity of ERE-1, ERE-3, ERE-
4 or ERE-5 to ERα was less apparent (Fig. 4A, lanes – 1, 3,
5, and 7). The complexes containing the ERE-1, -3, -4 and
-5 oligonucleotides migrated as a faint single band (Fig.
4A, lanes – 1, 3, 5, and 7) corresponding to complex "C1".
The ERE-2 formed two complexes, C1 and far predomi-
nant C2, (Fig. 4A, lane – 12). The "putative" ERE-6 also
revealed two types of complexes equivalent to C1 and C3
(Fig. 4A, lanes 10, 26 and 28). The complexes C1, C2 and
C3 were observed usually when the binding reaction was
kept at room temperature. However, if the binding reac-
tion was performed on ice, an intermediate complex(es)
appeared (Fig. 4A, lane 24, band*).
The specificity of ERα binding to the MUC1 promoter
EREs was validated by the ability of anti-ERα antibodies to
partially or completely inhibit binding ERE (Fig. 4A, lanes
– 2, 4, 6, 8, 11 and 13; Fig. 4B, lanes – 2, 7 and 12). Nor-
mal rabbit serum failed to inhibit the binding of ERα (Fig.
4B, lanes – 3, 8 and 13). The mutated ERE sequences did
not bind ERα (Fig. 4B, lanes – 4, 9 and 14). The electro-
phoretic profiles of the products obtained in reaction with
mutated oligonucleotides could not be changed by anti-
ERα antibodies (Fig. 4B, lanes – 5, 10 and 15). Moreover,
corresponding "cold" ERE-oligonucleotides (Fig 4A, lanes
15–18, 22–25 and 29–32) but not irrelevant oligonucle-
otide OCT-1 (Fig 4A, lanes 14, 21 and 28) successfully
competed-out binding of ERα to specific ERE-containing
oligonucleotides. In conclusion, our results demonstrate
the ability of the MUC1 promoter EREs to specifically
Effect of estrogen and 4-hydroxytamoxifen (4-OHT) on expression of MUC1 isoform specific mRNA in T47D and MCF7 cells  analyzed by RT-PCR Figure 3
Effect of estrogen and 4-hydroxytamoxifen (4-OHT) on expression of MUC1 isoform specific mRNA in T47D 
and MCF7 cells analyzed by RT-PCR. Human T47D (clone 10) and MCF7 cells were cultured in DMEM medium with or 
without estrogen and 4-OHT supplements as described in "Materials and Methods". Total RNA was extracted and MUC1 iso-
form specific RT-PCR was performed. Lane M-DNA marker; lane 1 – cells grown in the medium without estrogen; lanes 2, 3 
and 4 – cells grown with 0.1 nM, 1 nM and 10 nM estrogen, respectively; lanes 5, 6 and 7 – cells grown with 10 nM estrogen 
and with 10 nM, 100 nM and 1 μM 4-OHT supplements, respectively.
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bind ERα in vitro. Further experiments will be needed to
study the interaction between ERα and MUC1 specific
EREs in vivo.
Discussion
The expression of multiple isoforms of the MUC1 gene
[2,4,7,9] in a variety of cell types [2-6] and the active role
of the gene in different physiological processes [9] suggest
a fine-tuned transcriptional regulation. Some specific
questions that we have addressed in this study include: 1)
Does the MUC1 promoter regulate differential expression
of isoform specific mRNAs? 2) Is the expression of human
MUC1 gene transfected into heterologous (mouse) cells
relevant to its endogenous expression in homologous
(human) cells? 3) How does estrogen regulate MUC1
transcription? Some of these questions have been
answered in this study, others are still issues for our ongo-
ing investigations.
Numerous overlapping and densely distributed cis-ele-
ments that potentially could bind a multitude of tran-
scription factors demonstrate the structural and
functional complexity of the MUC1 promoter. Further
evidence of the MUC1 promoter complexity is the pres-
ence of several elements that participate in the develop-
ment of RNA-Pol II initiation complexes (TATA-boxes,
GC-boxes and initiators) and multiple transcription start
sites (CAP-sites).
Usually, eukaryotic promoters that regulate transcription
by RNA polymerase II belong to one of four types: 1)
TATA-box-containing promoter (facultative genes) [21];
2) GC-box-containing promoter (housekeeping genes)
[22]; 3) Initiator-containing promoter (first described in
genes expressed in B-cells) [23]; 4) "Dual" promoter that
have both TATA- and GC-elements and drive both TATA-
and GC-boxes specific transcription (found in cathepsin
ERα binding to EREs detected in the MUC1 promoter Figure 4
ERα binding to EREs detected in the MUC1 promoter. The EMSA of the complexes (C1, C2 and C3) developed by 
ERα from T47D nuclear lysate and 32P-labeled oligonucleotides containing the MUC1 promoter EREs (for details see "Materials 
and Methods"). A: Binding of ERα to 32P-labeled oligonucleotides ERE1, ERE2, ERE3, ERE4 and ERE5, containing 1/2 consensus 
core sequence of the classical ERE, and to palindrome like ERE (putative ERE-6 and Vit ERE). Lanes 1, 3, 5, 7, 10, 12, 19 and 26 
– complexes developed in absence of anti-ERα Ab; lanes 2, 4, 6, 8, 11, 13, 20 and 27 – partial or complete inhibition of complex 
formation by anti-ERα Ab; lanes 14, 21 and 28 – binding of ERα to 32P-ERE2, Vit-ERE and ERE6, respectively, in the presence of 
"cold" Oct1 oligonucleotide; lanes 15–18 – binding of ERα to 32P-ERE2 in presence of decreasing amount of the "cold" ERE2; 
lanes 22–25 – binding of ERα to 32P-Vit ERE in presence of decreasing amount of the "cold" Vit ERE (* indicates an intermedi-
ate complex developed when binding reaction was kept on ice); lanes 29–32 – binding of ERα to 32P-ERE6 in presence of 
decreasing amount of the "cold" ERE6. B: Effects of anti-ERα Ab and normal rabbit serum (NRS) on ERα binding to MUC1 spe-
cific and mutated EREs. Lanes 1, 6 and 11 – binding of ERα in absence of anti-ERα Ab; lanes 2, 7 and 12 – partial or complete 
inhibition of binding complexes by anti-ERα Ab; lanes 3, 8 and 13 – binding of ERα in presence of NRS; lanes 4, 9 and 14 – bind-
ing of ERα to mutated ERE in absence of anti-ERα Ab; lanes 5, 10 and 15 – binding of ERα to mutated ERE in presence of anti-
ERα Ab.
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D and methallotheonin genes) [27]. The MUC1 promoter
demonstrates properties characteristic for promoters of
different types. It contains several TATA- and GC-boxes
and a number of initiators (see "Additional files 1, 2, 3").
It contains multiple cis-elements that potentially tran-
scribe the MUC1 gene in many different cell types and tis-
sues and cis-elements specific for viral promoters
[2,3,5,28-30]. These peculiarities of the MUC1 promoter
allow us to classify it as a "mixed polypotent promoter".
We believe that studies of eukaryotic transcription will
reveal increasing number of genes with this type of pro-
moter.
Our bioinformatic study of the MUC1 promoter resulted
in construction of the MUC1 cis-element map. This map
has several advantages. Using the map, one may design a
functional analysis of transcription factors potentially
competing for overlapping cis-elements in the MUC1 pro-
moter. It also allows prediction of cells in which the
MUC1 gene might be expressed. Based on the content of
the MUC1 cis-elements, we predicted expression of the
MUC1 gene in lymphoid and muscle cells that had been
thought to be MUC1 non-producing cells. Subsequently,
the MUC1 expression in these cells was confirmed experi-
mentally [5]. Obviously, in a single study it is impossible
to evaluate functional activities of all cis-elements
detected in the MUC1 promoter. Nevertheless, several cis-
elements that were identified by our bioinformatic
approach (MZF-1, Sp1 and STAT) have been already
found active in transcriptional regulation of the MUC1
gene in vivo [28-30].
Transient transfection of plasmids that have different
deletions within the promoter DNA can identify promoter
regions necessary for the expression of specific mRNA iso-
forms. We combined this approach with our bioinformat-
ics information to experimentally characterize the MUC1
promoter activity. In our study, the Dpr plasmid that con-
tained a full-length MUC1 promoter supported expres-
sion only of the MUC1/SEC isoform (Fig. 1B, lane – 1). In
contrast, the plasmid DprΔ2154 lacking a ~2 kb fragment
deleted from the 5'-end of the promoter demonstrated
higher activity and supported expression of both MUC1/
SEC and MUC1/TM mRNA (Fig. 1B, lanes – 4 and 5,
respectively), indicating that within the deleted fragment
are transcriptional repressor binding sites. Our cis-ele-
ment map supports this hypothesis, since the deleted frag-
ment of the MUC1 promoter (-2872/-718) contains
multiple binding sites for transcriptional repressors: 9
sites for δEF1-repressor (-2180/-2170, -1546/-1536, -
1522/-1512, -1486/-1476, -1462/-1452, -1418/-1408, -
1175/-1165, -1029/-1019 and -1008/-998), 7 sites spe-
cific for the Gfi-1 repressor (-2627/-2515, -2589/-2574, -
2530/-2515, -1738/-1723, -1435/-1420, -1306/-1291 and
-1141/-1126), 5 sites specific for YY1-repressor (-2786/-
2776, -2772/-2762, -1428/-1418, -1395/-1385 and 1203-
1193) and a single ELP repressor binding site (-1172/-
1165) (see "Additional files 1, 2").
Plasmid DprΔ2446, lacking an additional 292 bp, elevates
MUC1/TM expression but leads to a decrease in the
expression of the MUC1/SEC mRNA compared to
DprΔ2154 (Fig 1B, lanes – 7 and 8). These observations
suggest that the deleted 292 bp fragment might contain
both additional sites for MUC1/TM mRNA repressors as
well as sites important for MUC1/SEC expression. Indeed,
as the map shows, the deleted fragment contains cis-ele-
ments specific for two repressors, YY1- (-670/-660) and
δEF1- (-472/-462), in addition to several cis-elements spe-
cific for mammary epithelial cell activators: CTF/NF,
ESE1, MAF, MGF, MP4 and RME [31-34] (see "Additional
file 3").
According to results obtained with the DprΔ2839 plas-
mid, a minimal set of transcription elements (one TATA-
box, one CAP-site and several cis-elements specific for
transcriptional activators RCE, SRE and ETF-RE) (see
"Additional file 3") is sufficient for expression of MUC1/
SEC isoform (Fig. 1B, lane – 10). Transcriptional activity
of the minimal MUC1 promoter has been observed in
transfection studies [35,36]. Notably, two very different
plasmids, one of which contains the full MUC1 promoter
(Dpr) and the other which contains only a minimal pro-
moter sequence (DprΔ2839), drive similar expression of
the MUC1/SEC isoform. It appears that in our experimen-
tal conditions, the positive and negative effects of the cis-
elements in the full promoter seem to balance-out each
other resulting in expression of MUC1/SEC similar to that
of the minimal promoter.
The results demonstrating higher activity of the truncated
promoter (DprΔ2154, DprΔ2446) compared to the full
length MUC1 promoter (Dpr) are not surprising. Earlier,
Kovaric et al [36] showed that expression of the CAT-test
gene driven by the full length MUC1 promoter was almost
half than that directed by 743 bp promoter fragment. Abe
and Kufe [35] also observed higher CAT activity when the
test-gene was driven by a smaller promoter fragment (-
686/+33) than by a larger one (-1656/+33). Moreover,
according to these authors, the 114 bp fragment of the
MUC1 promoter located between -598 and -485 bp dem-
onstrated the highest CAT gene expression. Superimposi-
tion of the promoter fragments analyzed in these studies
and our MUC1 cis-element map leads to similar schemat-
ics of activating and repressing regions.
One of the issues addressed in our research was whether
the expression of the human MUC1 gene transfected into
heterologous (mouse) cells is relevant to its endogenous
expression in homologous (human) cells. The resultsMolecular Cancer 2006, 5:57 http://www.molecular-cancer.com/content/5/1/57
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described in this study showed that in our experimental
conditions, the patterns of the MUC1 gene expression in
both cell systems were different. In mouse cells, human
MUC1 gene (Dpr plasmid) directed expression of the
MUC1/SEC isoform, whereas in human cells, the predom-
inant mRNA was MUC1/TM. In transfected mouse DA3
cells, we could not detect human MUC1/Y isoform,
whereas in human T47D and MCF7 cells this isoform was
observed. The basis for such differential expression is pres-
ently being studied.
One of the important issues in regulation of MUC1
expression is the role of estrogen and estrogen receptors.
Several studies have showed that the MUC1 gene posi-
tively responds to estrogen [16-19]. However, in our
study, we observed that not all MUC1 isoforms responded
to estrogen in the same manner. The MUC1/SEC mRNA
was expressed in T47D cells (ER+ clone 10) only after
treatment with estrogen. In contrast to T47D cells, in ER-
positive MCF7 cells, expression of the MUC1/SEC mRNA
was observed in the absence of estrogen, although, simi-
larly to T47D cells, estrogen increased and 4-OHT
decreased its expression. The MUC1/TM mRNA could be
expressed both in T47D estrogen receptor positive cells
(clone 10) and estrogen receptor negative cells (clone 8)
as well as in MCF7 cells. Moreover, this expression was
not affected by 4-OHT. The dependence of the MUC1/Y
isoform expression on estrogen and ER was not clear cut.
On one hand, we observed some increase in MUC1/Y
expression in T47D and MCF7 cells after estrogen treat-
ment but on the other hand, 4-OHT did not inhibit its
expression. Further experiments will be needed to clarify
this matter.
The above data suggest that the expression of MUC1 iso-
forms in MCF7 cells somehow differs from their expres-
sion in T47D cells. Perhaps relevant to our observations is
that MCF7 and T47D cells express different levels of ster-
oid receptors. In MCF7 cells, ER is expressed at much
higher levels than progesterone receptors (PR), whereas in
T47D cells, the expression of PR is higher than that of ER
[37,38]. Since estrogen regulates the transcription of the
ER gene [39], it appears that T47D cells may require exog-
enous supplements of estrogen to activate expression of
the ER gene. In contrast, the endogenous expression levels
of estrogen receptors in MCF7 cells might be high enough
to support expression of the MUC1/SEC isoform. In
accordance with our results, Hurd et al [40] observed
expression of hyperphosphorylated retinoblastoma pro-
tein (ppRB) in MCF7 but not in T47D cells when cells
incubated without estrogen. A gradual increase of its
expression after treatment with estrogen was observed in
MCF7 cells in time-dependent manner. In T47D cells,
longer estrogen treatment was necessary to detect ppRB
than in MCF7 cells.
Our data demonstrating the responsiveness of the MUC1/
SEC isoform expression in human epithelial cells to
inhibitory effects of 4-OHT are in agreement with obser-
vations that the expression of MUC1 gene in human ade-
nocarcinoma cells is also sensitive to antiestrogens
[41,42]. These data suggest that, in human cells, estrogen
may regulate the MUC1 gene transcription by interaction
with ER directing them to cis-ERE in MUC1 promoter. The
results obtained by us with EMSA using T47D cell lysates
support this hypothesis. However, they are in contradic-
tion with the observations made in a mouse system. Stud-
ying the role of ER in transcriptional regulation of the
mouse Muc1 gene, Zhou et al [18] concluded that ER did
not directly bind to the cis-ERE of the murine Muc1 pro-
moter. We found that all cis-ERE detected in the human
MUC1 promoter could form complexes with human ERα
in vitro. Several factors may explain this discrepancy. First,
different  cis-EREs were used in both studies. Although
human and mouse MUC1 promoters have high degree of
homology, their cis-EREs demonstrate pronounced diver-
sity. We have analyzed the mouse Muc1 and human
MUC1 promoter sequences and found that each promoter
contains six cis-EREs. Comparison of these elements
revealed both homology and differences in their
sequences. Second, Zhou et al [18] analyzed binding of
estrogen receptors that have been in vitro translated,
whereas in our binding assays we used ERα endogenously
synthesized in T47D cells that express human MUC1
gene.
It should be noted, that, although all MUC1 cis-EREs
bound ERα, the properties of the complexes developed by
different cis-EREs were different. Several cis-EREs, (ERE1,
ERE3, ERE4 and ERE5) containing only half of the classi-
cal palindrome sequence produced a weak, fast migrating
complex with ERα. Interestingly, ERE2, which also con-
tains only half of the ERE palindrome sequence, devel-
oped two complexes that at least partially correspond to
those observed with classical ERE from the vitellogenin
gene and with "putative" ERE-6 of the MUC1 gene. The dif-
ferent electrophoretic mobility of the complexes might be
explained by content of ER-cofactors in the complexes. It
is not clear why oligonucleotides that have identical or
very similar ERE core sequences recruit different cofactors
to ER-containing complexes, however, the flanking
sequences may play a crucial role in this process [43].
Importantly, all complexes developed with tested cis-ERE
contained ERα since the binding of ERα was specific and
could be inhibited by antibodies developed against the
DNA-binding domain of human ERα.
Whereas our in vitro studies clearly showed that physical
binding of ERα with cis-EREs of the MUC1 promoter
occurs, definitive in vivo binding still remains to be
proven. Orientation of ERE within the synthetic oligonu-Molecular Cancer 2006, 5:57 http://www.molecular-cancer.com/content/5/1/57
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cleotides appears not to be important for in vitro binding,
but orientation and distribution of EREs among cis-ele-
ments within promoter, are presumably crucial for proper
in vivo binding [44-46]. A special approach will be needed
to study this issue. In the MUC1 promoter, two estrogen
responsive elements (ERE-1 and the "putative" ERE-6),
have direct sequence orientation while others (ERE-2,
ERE-3, ERE-4 and ERE-5) have opposite orientation.
Three elements (ERE-1, ERE-2 and ERE-3) are located rel-
atively distant from the active TATA-box and from each
other. Three others (ERE-4, ERE-5 and the "putative" ERE-
6) are located in close proximity to each other between
nucleotides -389 and -337 (see "Additional files 1, 2, 3")
and may function as an estrogen responsive unit [47,48].
Very few mRNAs that are known to be directly regulated
by estrogen in mammary epithelial cells are actually
induced via canonical EREs [49]. In fact, most estrogen-
responsive genes identified to date contain one or more
imperfect EREs or multiple copies of an ERE half-site
rather than the classical ERE [50,51]. The MUC1 cis-EREs
also are not absolutely identical to the consensus
sequence. Although the affinity of the estrogen receptor
for the classical ERE is higher than for imperfect ERE-like
sequences, most of the imperfect EREs bind ER [52]. The
MUC1  cis-EREs, although imperfect, also bound ER in
vitro. It is becoming clear that EREs function as allosteric
modulators of ER conformation [53,54]. The conforma-
tional changes in ER induced by individual ERE sequences
lead to specific association of the receptor with other tran-
scription factors and assist in differential transcription of
estrogen-responsive genes [54,55]. In light of these data,
the imperfect MUC1 cis-EREs might be significant, per-
haps by differential usage of ERE in diverse cells recruiting
distinct cofactors for the MUC1 expression.
We have discussed the possible involvement of ER and
MUC1 EREs in regulation of the MUC1 gene transcrip-
tion. However, it is known that ER may regulate gene tran-
scription also by interaction with other transcription
factors (STAT, AP1, EGFR or NFkB) without direct binding
to ERE [56]. Further studies are needed to understand the
process of MUC1 transcription in vivo and to elucidate the
mechanism by which estrogen activates transcription of
the MUC1 gene.
Although our study revealed some new and important fea-
tures of the MUC1 promoter cis-element content and
structure, the precise mechanisms by which these cis-sites
are involved in the regulation of MUC1 expression have
not been fully elucidated. On one hand, elements within
the promoter could determine usage of different transcrip-
tion start sites specific for individual MUC1 isoforms. The
presence of multiple CAP-sites in the MUC1 promoter
together with previously documented multiple transcrip-
tion start sites of the MUC1 gene in T47D cells [11] sup-
port this hypothesis. On the other hand, the promoter cis-
elements might be involved in regulating of alternative
splicing of a single pre-mRNA common to all MUC1 iso-
forms. A growing body of evidence suggests that transcrip-
tion and splicing are highly coordinated processes both at
the structural and functional levels [57-61]. For instance,
it has been shown that mutations introduced into pro-
moter cis-elements could change the alternative splicing
patterns [58]. Moreover, the RNA pol II large subunit
physically associates with spliceosomes and the SR pro-
teins that regulate alternative splicing act through specific
promoter occupation [62].
In light of these data, we suggest that cis-elements of the
MUC1 promoter may be involved in mechanisms that
regulate both transcription and splicing of the MUC1 pre-
mRNAs. In this study, we used total RNA extracted from
transfected cells. However, for a better understanding of
the role of the MUC1 promoter in transcription and splic-
ing of MUC1 isoforms, an additional study of the 5'-ends
of nuclear pre-mRNA is needed. Additionally, the effect of
different mutations within cis-sites of the MUC1 promoter
on isoform expression could be more thoroughly dis-
sected. These experiments are currently in progress.
Conclusion
In this study several important findings have been
revealed. First, transcription cis-elements of the MUC1
promoter have been identified and the map of these ele-
ments has been constructed. The advantage of such a map
is that it not only shows the content of the promoter cis-
elements but exemplifies the transcription factors poten-
tially competing for specific binding sites. Second, we
established that different regions of the MUC1 promoter
may control expression of different MUC1 isoform RNAs.
We also observed differential expression patterns of the
human MUC1 gene in heterologous (mouse) and homol-
ogous (human) cells. Third, we showed, for the first time,
that estrogen can differentially regulate the expression of
some MUC1 isoforms. For instance, estrogen activated
expression of MUC1/SEC, but not MUC1/TM isoform in
human breast cancer epithelial cells. Fourth, we found six
cis-ERE in the MUC1 promoter and showed that they can
bind ERα  in vitro. Our findings may help to develop
molecular modalities for controlled regulation of the
MUC1 gene expression and thus may contribute to
progress in molecular-based breast cancer therapy.
Methods
Computer analysis of potential transcription cis-elements
The computer analysis of the potential transcription cis-
elements of the MUC1 promoter has been performed by
using the TRANSFAC (MatInspector V2.2) and TSSG data-
bases of transcription factors and their DNA binding sitesMolecular Cancer 2006, 5:57 http://www.molecular-cancer.com/content/5/1/57
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[63,64]. The 2.9 kb MUC1 promoter sequence was
obtained from the GENE Bank NCBI: accession #-
X69118. For construction of the MUC1 promoter cis-ele-
ment map we used mainly those cis-elements whose
sequence homology with corresponding consensus
sequences was significantly high (0.75–1.0).
Cells
Human breast cancer cell lines MCF-7, T47D and MDA-
231 and mouse breast cancer DA3 cells were cultured in
full DMEM medium with 10% foetal calf serum (FCS),
penicillin (100 u/ml), streptomycin (100 μg/ml) at 37°C
in 5% CO2. One week before estrogen treatment, cells
were transferred to phenol red-free DMEM medium con-
taining antibiotics and 5% charcoal-treated FCS. The con-
centration of FCS was reduced to 1% one day before
adding of 0.1–10 nM 17β-estradiol (E2) only or in com-
bination with 10 nM – 1 μM 4-hydroxytamoxifen (4-
OHT) (Sigma). Cells were incubated for 24 hours and
then were harvested for RNA preparation.
Plasmids
The plasmid Dpr (pDpr) containing the human MUC1
full-length promoter and MUC1 coding sequence was
constructed on a polyIII plasmid backbone [65]. The
genomic MUC1 sequence was inserted into ppolyIII at the
EcoRI site. The recombinant plasmid was then digested
with restriction enzyme PvuI generating two fragments of
6946 bp and 666 bp. The bigger fragment contained a part
of ppolyIII, the full MUC1 promoter sequence (2872 bp)
and all MUC1 exons and introns except for a part of cyto-
plasmic domain coding DNA. This DNA fragment
together with 150 bp SV40 polyA sequence and 600 bp of
the ppolyIII was isolated from the pCL642/MUC1/TM by
PvuI digestion [11]. The obtained PvuI/PvuI 870 bp frag-
ment was ligated with 6946 bp PvuI/PvuI fragment result-
ing in generation of pDpr. This plasmid contained the
full-length promoter and the full coding region of the
MUC1 gene. It was used for generation of deletions in the
promoter region (Fig. 1A). The first deletion mutant of the
MUC1 promoter was constructed by excision of 2154 bp
promoter region from the pDpr by SacI digestion fol-
lowed by self-ligation of the rest of the pDpr. The resultant
plasmid, pDprΔ2154, lacks the 5'-end 2154 bp promoter
fragment. The next deletion mutant designated
pDprΔ2446 represented the pDpr without 5'-end 2446 bp
promoter sequence. The promoter region of the
pDprΔ2446 is 292 bp shorter at the 5'-end than promoter
fragment of the pDprΔ2154. The pDprΔ2446 was gener-
ated by SacI/AgeI excision of almost full MUC1 promoter
followed by insertion into the rest of pDpr sequence of the
PCR product that covered the region between -426 and -
33 nucleotides of the MUC1 promoter. The primers used
for synthesis of the insert were:
5' AATCTAGAGCTCGCTCTGCTTCAGTGG 3' (forward)
(the underlined sequence is SacI restriction site)
5' GCTTTATACCGGTCCCCCCACTCCCCG 3' (reverse)
(the underlined sequence is AgeI restriction site)
The third promoter deletion mutant, pDprΔ2839, con-
tained only 33 bp MUC1 promoter sequence (-33/+1)
and included the TATA-box and several transcription cis-
elements. It was constructed by excision of the 5' 2839 bp
from the pDpr by SacI/AgeI digestion and ligation of the
rest of the pDpr with the SacI-AgeI adapter.
Transient transfection assay
Transient transfection assays were performed in 60 mm
Petri dishes. Plasmid DNA (5 μg) was transfected into
DA3 cells by Lipofectin as described by the manufacturer.
Efficiency of transfection was evaluated by simultaneous
transfection of GFP-expression plasmid. After 48 hours
cells were harvested for RNA preparation and RT-PCR
analysis.
RT-PCR
Total RNA was isolated from the cells using TRIzol Rea-
gent (Gibco BRL). cDNA was synthesized by EZ-First
Strand cDNA Synthesis Kit for RT-PCR (Biological Indus-
tries, Beit Haemek Ltd, Israel) according to the manufac-
turer. The complementary DNA products from RT
reactions were amplified by PCR in the presence of the
appropriate primers:
MUC1/SEC (forward): 5' TTCCCAGCCACCACTCTGA-
TACT 3'
MUC1/SEC (reverse): 5' AGCATGGGGAAGGAAAGG 3'
MUC1/TM (forward): 5' TTCCCAGCCACCACTCTGA-
TACT 3'
MUC1/TM (reverse): 5' GACATTGATGGTACCTTCTCG 3'
MUC1/Y (forward): 5' GTATAAAACGGAAGCAGCCTCTC
3'
MUC1/Y (reverse): 5' GAGAGGCTGCTTCCGTTTTATAC
3'
Actin (forward): 5' GTTTGAGACCTTCAACACCCC 3'
Actin (reverse): 5' GTGGCCATCTCTTGCTCGAAGTC 3'
The MUC1 and actin specific fragments were amplified
using the following PCR conditions: denaturation at 94°C
for 5 min, then 35 cycles of 94°C for 45 sec, 50°C for 45
sec and 72°C for 45 sec followed by final primer extentionMolecular Cancer 2006, 5:57 http://www.molecular-cancer.com/content/5/1/57
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of 72°C for 5 min. All transcripts were analyzed in parallel
on at least three separate occasions in a thermal cycler.
PCR products were analyzed by electrophoresis on 1.2%
agarose gel and visualized by ethidium bromide staining
under UV illumination.
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was carried out as described by Promega Protocol
[66]. The following oligonucleotides corresponding to
ERE present in MUC1 promoter (the bold underlined
sequence) in direct (ERE-1 and ERE-6) and inverted (ERE-
2, ERE-3, ERE-4 and ERE-5) orientation were annealed
with corresponding complementary oligonucleotides and
end-labeled with [γ-32P]ATP using T4 polynucleotide
kinase.
ERE-1 -2754 5' AGAGGGTGGTCACCCACCCTTC 3'-2733
ERE-2 -1182 5' TTGAACCCCTGACCTTGTGATCC 3'-1160
ERE-2 mut-1182 5' TTGAACCCCAGACATTGTGATCC 3'-
1160
ERE-3 -755 5' AAGGCTCCCGGTGACCACTAGAG 3'-736
ERE-4 -389 5' AGTGGGAGACCTAGGGGTGGG 3' -369
ERE-5 -371 5' GGGCTTCCCGACCTTGCTGTA 3'-351
ERE-6 ("putative") -351 5' TACAGGACCTCGAC-
CTAGCTG 3' -332
ERE-6 mut -351 5'TACAAGATTTCGGACTAGCTG 3'-332
Vit-ERE 5'TCCAGGTCACTGTGACCCAAC 3'
Vit-EREmut 5'TCCAGGACTCTGTAACGCAAC 3'
Cell nuclear extract was prepared as described [67].
Nuclear extracts (2–5 μg) were incubated in 1 × Gel Shift
Binding Buffer (50 mM Tris, pH 7.5/4% glycerol/1 mM
MgCl2/0.5 mM EDTA/0.5 mM DTT/50 mM NaCl/0.05
mg/ml poly(dI-dC)poly(dI-dC) at room temperature for
10 minutes, and then 32P-labeled oligonucleotides
(80,000 cpm) were added and incubation at room tem-
perature was continued for 20 minutes. The anti-ERα anti-
body [anti-ERα Ab (D-12), catalog # x:sc-8005X, Santa
Cruz Biotechnology] used in the study were raised against
DNA-binding domain of human ERα (amino acids 2–185
mapping at the N-terminus). Incubation of the binding
reaction mixture with anti-ERα Ab was performed for 1 hr
at room temperature or overnight at 4°C before adding
labeled ("hot") oligonucleotides. Competing non-labeled
("cold") oligonucleotides, or non-relevant OCT1 oligonu-
cleotide were added to reactions simultaneously with
"hot" 32P-ERE oligonucleotide probe. 1 μl of 10× loading
buffer was added per reaction to stop binding and reac-
tion products were analyzed by electrophoresis in 6%
DNA retardation gel in 0.5 × TBE buffer at 290 V. Gel was
dried on a gel dryer and exposed to Kodak X-ray film at -
70°C with an intensifying screen.
Statistics
All transfection assays and expression PCR analysis as well
as EMSA experiments were performed in parallel on at
least three separate occasions.
Abbreviation
All abbreviation of transcription factors and correspond-
ing cis-elements are from [63,64].
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